NCT04854642View on ClinicalTrials.gov

A Single Dose Study About the Influence of Food on the Oral Bioavailability of Ladarixin Capsule in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 20, 2020

Primary Completion Date

December 9, 2020

Study Completion Date

December 9, 2020

Conditions
no Condition
Interventions
DRUG

Ladarixin

A single oral dose of 400 mg of ladarixin (two 200 mg capsules) was administered to healthy male and female volunteers under fed (Test treatment) and fasting (Reference treatment) conditions in two consecutive study periods, according to a two-way crossover design, with a wash-out interval of at least 14 days between the two administrations.

Trial Locations (1)

6864

CROSS Research S.A., I Unit, Arzo

All Listed Sponsors
lead

Dompé Farmaceutici S.p.A

INDUSTRY

NCT04854642 - A Single Dose Study About the Influence of Food on the Oral Bioavailability of Ladarixin Capsule in Healthy Volunteers | Biotech Hunter | Biotech Hunter